CN116157411A - SARS-CoV-2衍生氨基酸序列及其应用 - Google Patents

SARS-CoV-2衍生氨基酸序列及其应用 Download PDF

Info

Publication number
CN116157411A
CN116157411A CN202180058673.0A CN202180058673A CN116157411A CN 116157411 A CN116157411 A CN 116157411A CN 202180058673 A CN202180058673 A CN 202180058673A CN 116157411 A CN116157411 A CN 116157411A
Authority
CN
China
Prior art keywords
amino acid
synthetic peptide
acid sequence
serum
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058673.0A
Other languages
English (en)
Chinese (zh)
Inventor
吉田彻彦
贝利小林菜穗子
吉田善纪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toagosei Co Ltd
Kyoto University NUC
Original Assignee
Toagosei Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toagosei Co Ltd, Kyoto University NUC filed Critical Toagosei Co Ltd
Publication of CN116157411A publication Critical patent/CN116157411A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
CN202180058673.0A 2020-07-31 2021-07-30 SARS-CoV-2衍生氨基酸序列及其应用 Pending CN116157411A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-131022 2020-07-31
JP2020131022 2020-07-31
PCT/JP2021/028366 WO2022025264A1 (ja) 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Publications (1)

Publication Number Publication Date
CN116157411A true CN116157411A (zh) 2023-05-23

Family

ID=80035853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058673.0A Pending CN116157411A (zh) 2020-07-31 2021-07-30 SARS-CoV-2衍生氨基酸序列及其应用

Country Status (5)

Country Link
US (1) US20230272005A1 (https=)
EP (1) EP4190799A4 (https=)
JP (1) JP7747273B2 (https=)
CN (1) CN116157411A (https=)
WO (1) WO2022025264A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022308712A1 (en) * 2021-07-09 2023-12-21 Atossa Therapeutics, Inc. Compositions and methods to increase coronavirus immune response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609119A (zh) * 2003-10-23 2005-04-27 中国医学科学院药物研究所 一种肽文库、其合成方法及从该文库中筛选的活性片段

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028219A (ja) * 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン
JP7297697B2 (ja) 2019-02-19 2023-06-26 キヤノンメディカルシステムズ株式会社 神経活動の領域を推定する推定方法、推定装置及び磁気共鳴イメージング装置
BR102019017792A2 (pt) * 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
JP2023512519A (ja) * 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
WO2021181390A1 (en) * 2020-03-09 2021-09-16 Vaxil Biotherapeutics Ltd. Antigen specific epitope–based anti-infective vaccines
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609119A (zh) * 2003-10-23 2005-04-27 中国医学科学院药物研究所 一种肽文库、其合成方法及从该文库中筛选的活性片段

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEEMA MISHRA等: "T cell epitope-based vaccine design for pandemic novel coronavirus 2019-nCoV across structural and non-structural proteins", pages 1 - 15, Retrieved from the Internet <URL:<https://chemrxiv.org/engage/chemrxiv/article - details/60c749b4469df4724cf43c17>，<DOI:10.26434/chemrxiv.12029523.v2 ]> *
YOYA VASHI等: "Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens", INFECT GENET EVOL., vol. 84, no. 104382, 27 May 2020 (2020-05-27), pages 1 - 7 *

Also Published As

Publication number Publication date
JP7747273B2 (ja) 2025-10-01
WO2022025264A1 (ja) 2022-02-03
EP4190799A1 (en) 2023-06-07
US20230272005A1 (en) 2023-08-31
EP4190799A4 (en) 2024-08-21
JPWO2022025264A1 (https=) 2022-02-03

Similar Documents

Publication Publication Date Title
CN112557645B (zh) 抗原表位多肽的筛选方法及装置
WO2021248853A1 (zh) 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
Tian et al. Structure− affinity relationships in the gp41 ELDKWA epitope for the HIV‐1 neutralizing monoclonal antibody 2F5: effects of side‐chain and backbone modifications and conformational constraints
JP5187883B2 (ja) 抗原ペプチドおよびその利用
Zhao et al. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates
CN104619338A (zh) 稳定化的gp120
US20100278853A1 (en) Constrained hiv v3 loop peptides as novel immunogens and receptor antagonists
JPH02503916A (ja) Ｈｉｖエンベロープ蛋白質に関連する合成ペプチド
Martínez-Torrecuadrada et al. Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides
Valero et al. Native‐like cyclic peptide models of a viral antigenic site: finding a balance between rigidity and flexibility
CN116157411A (zh) SARS-CoV-2衍生氨基酸序列及其应用
CN116496389A (zh) 用于治疗hbv感染及相关疾病的表位肽及抗体
JPH05508838A (ja) Ｈｔｌｖ―ｉおよびｈｔｌｖ―ｉｉウイルスに対する抗体を検出するためのペプチドおよびアナログおよびその混合物
US12285476B2 (en) Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody
Skwarczynski et al. Group A streptococcal vaccine candidates based on the conserved conformational epitope from M protein
Geerligs et al. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice
Obeid et al. Identification of helper T cell antigenic sites in mice from the haemagglutinin glycoprotein of measles virus
JPH07501710A (ja) エプスタイン・バールウイルスのペプチド及びこれらのペプチドに対する抗体
EA005313B1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
JPS63264600A (ja) ウシ白血病ウイルスに対する感染防御抗体を誘導するペプチド分画と、この分画を得る方法と、この分画の遺伝暗号配列と、この分画から製造されるワクチン
Saravanan et al. Diagnostic and immunoprophylactic applications of synthetic peptides in veterinary microbiology
Rudometov et al. The structural and immunological properties of chimeric proteins containing HIV-1 MPER sites
US20240091346A1 (en) Epstein barr virus vaccines
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination